The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors

Haematologica

Volumn 90, Issue 11, 2005, Pages 1562-1569

  Shaw, Bronwen E ^a   Russell, Nigel H ^a   Devereux, Steve ^b   Das Gupta, Emma ^a   Mackinnon, Stephen ^c   Madrigal, Jose Alejandro ^d   Pagliuca, Anthony ^b   Mufti, Ghulam J ^b   Byrne, Jennifer L ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Anthony Nolan Research Institute   (United Kingdom)

Author keywords

Primary non engraftment; Reduced intensity conditioned; Unrelated donors

Indexed keywords

ALEMTUZUMAB; BUSULFAN; FLUDARABINE; MELPHALAN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BONE MARROW CELL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DONOR; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; RECIPIENT; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE; SURVIVAL RATE;

EID: 27844520392     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Shaw BE, Madrigal JA, Potter M. Improving the outcome of unrelated donor stem cell transplantation by molecular matching. Blood Rev 2001; 15:167-74.
2. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
3. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16: 2817-24.
4. Nagler A, Aker M, Or R, Naparstek E, Varadi G, Brautbar C, et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 2001;29:362-70.
5. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation, Blood 2001;97:631-7.
6. Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 2000;96:4096-102.
7. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Ass 1958;53:457-81.
8. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and post-grafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003;101:1620-9.
9. Kusumi E, Kami M, Yuji K, Hamaki T, Murashige N, Hori A, et al. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Bone Marrow Transplant 2004;33:697-702.
10. Shimoni A, Kroger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M, et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 2005;19:7-12.
11. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003;102:3052-9.
12. Petersdorf EW, Anasetti C, Martin PJ, Hansen JA. Tissue typing in support of unrelated hematopoietic cell transplantation. Tissue Antigens 2003;61:1-11.
13. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-62.
14. Cull GM, Haynes AP, Byrne JL, Carter GI, Miflin G, Rebello P, et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol 2000;108:754-60.
15. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002;99:1071-8.
16. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000:96:2419-25.
17. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997;90: 4705-9.
18. Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. European Group for Blood and Marrow Transplantation. Blood 2002; 100:761-7.
19. Tanimoto TE, Yamaguchi T, Tanaka Y, Saito A, Tajima K, Karasuno T, et al. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. Br J Haematol 2004;125:480-93.
20. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005-105:548-51.
21. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, et al. HLA-matched unrelated donor hematopoietic cell transplantation after non-myeloablative conditioning for patients with hematologie malignancies. Blood 2003-102:2021-30.
22. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002-99:4200-6.
23. Hoepfner S, Goerner M, Benner A, Henning P, Ho AD. Unrelated donor transplantation after reduced intensity conditioning as an approach for patients lacking related donors for allogeneic stem cell transplantation. J Hematother Stem Cell Res 2003; 12:331-9
24. Petersdorf EW, Gooley TA, Anasetti C, Martin PJ, Smith AG, Mickelson EM, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998-92:3515-20.
25. Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001;345:1794-800.
26. Georges GE, Maris M, Sandmaier BM, Malone DG, Feinstein L, Niederweiser D, et al. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. Int J Hematol 2002;76 Suppl 1:184-9.
27. Miflin G, Russell NH, Hutchinson RM, Morgan G, Potter M, Pagliuca A, et al. Allogeneic peripheral blood stem cell transplantation for haematological malignandes-an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant 1997;19:9-13.
28. Ringden O, Remberger M, Runde V, Bornhauser M, Blau IW, Basara N, et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999;94:455-64.
29. Remberger M, Ringden O, Blau IW, Ottinger H, Kremens B, Kiehl MG, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001;98:1739-45.
30. Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med 1977;296:61-6.
31. Favre G, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2003;32:873-80.
32. Stroncek DF, Confer DL, Leitman SF. Peripheral blood progenitor cells for HPC transplants involving unrelated donors. Transfusion 2000;40:731-41.
33. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S, et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Spanish Group for Allogenic Peripheral Blood Transplantation. Blood 2001;97:383-7.
34. Petersdorf EW, Longton GM, Anasetti C, Mickelson EM, McKinney SK, Smith AG, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997;89:1818-23.
35. McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000;95:2219-25.